Authorized purpose: Support trained physicians in visualizing and evaluating physician-identified liver lesions on multi-phase reconstructed CT, including lesion size, shape, position, and change over time; not for standalone diagnosis or patient-management decisions.
Clinical role
Post-acquisition liver-lesion review and longitudinal analysis; the radiologist designates lesions, validates computed segmentations, and can manually correct them before semi-automatic matching and quantification.
Keep in mind: The physician must identify lesions and validate or manually correct computed segmentations and matching. Results must not be used in isolation for diagnosis or patient management. The reviewed FDA performance data are based on a retrospective liver-lesion dataset and a dedicated phantom study; local scanner, protocol, interface, and clinical-population compatibility require confirmation.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Support trained physicians in visualizing and evaluating physician-identified liver lesions on multi-phase reconstructed CT, including lesion size, shape, position, and change over time; not for standalone diagnosis or patient-management decisions.
Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Liver (physician-identified liver lesions) Input: Multi-phase volume datasets of reconstructed contrast-enhanced CT scans in DICOM format received from PACS, with physician-identified liver lesions; compatible CT vendors and models are subject to the device labeling's DICOM requirements.
Who uses it?Intended users: Trained physicians, including radiologists and other physicians managing the patient.
What does the software produce?Output: Quantitative liver-lesion volumes and locations in prior and current scans, lesion diameter and volume, total lesion burden, volume and diameter change over time, existing/new/disappeared lesion labels, RECIST measurements, key slices, and DICOM-transferred processing results.
What is its most important limitation?Key limitation: The physician must identify lesions and validate or manually correct computed segmentations and matching. Results must not be used in isolation for diagnosis or patient management. The reviewed FDA performance data are based on a retrospective liver-lesion dataset and a dedicated phantom study; local scanner, protocol, interface, and clinical-population compatibility require confirmation.
Clinical takeaway. Clinical role: Support trained physicians in visualizing and evaluating physician-identified liver lesions on multi-phase reconstructed CT, including lesion size, shape, position, and change over time; not for standalone diagnosis or patient-management decisions.
Evidence takeaway. Evidence from the reviewed source record: FDA K231690 reports phantom testing on four scanner platforms and a retrospective standalone analysis of 108 patients from Israel, Italy, and the US, comprising 219 contrast-enhanced CT scans and 2,127 liver lesions. Three radiologists established the lesion ground truth. The reported performance evidence uses DICE, ASSD, SHD, volume, and RECIST measurements and includes volume and longitudinal-change agreement, not a diagnostic-detection endpoint.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Support trained physicians in visualizing and evaluating physician-identified liver lesions on multi-phase reconstructed CT, including lesion size, shape, position, and change over time; not for standalone diagnosis or patient-management decisions.
Post-acquisition liver-lesion review and longitudinal analysis; the radiologist designates lesions, validates computed segmentations, and can manually correct them before semi-automatic matching and quantification.
Multi-phase volume datasets of reconstructed contrast-enhanced CT scans in DICOM format received from PACS, with physician-identified liver lesions; compatible CT vendors and models are subject to the device labeling's DICOM requirements.
Quantitative liver-lesion volumes and locations in prior and current scans, lesion diameter and volume, total lesion burden, volume and diameter change over time, existing/new/disappeared lesion labels, RECIST measurements, key slices, and DICOM-transferred processing results.
The physician must identify lesions and validate or manually correct computed segmentations and matching. Results must not be used in isolation for diagnosis or patient management. The reviewed FDA performance data are based on a retrospective liver-lesion dataset and a dedicated phantom study; local scanner, protocol, interface, and clinical-population compatibility require confirmation.
FDA K231690 reports phantom testing on four scanner platforms and a retrospective standalone analysis of 108 patients from Israel, Italy, and the US, comprising 219 contrast-enhanced CT scans and 2,127 liver lesions. Three radiologists established the lesion ground truth. The reported performance evidence uses DICE, ASSD, SHD, volume, and RECIST measurements and includes volume and longitudinal-change agreement, not a diagnostic-detection endpoint.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
FDA K231690 reports phantom testing on four scanner platforms and a retrospective standalone analysis of 108 patients from Israel, Italy, and the US, comprising 219 contrast-enhanced CT scans and 2,127 liver lesions. Three radiologists established the lesion ground truth. The reported performance evidence uses DICE, ASSD, SHD, volume, and RECIST measurements and includes volume and longitudinal-change agreement, not a diagnostic-detection endpoint.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
iCAS-LV regulatory performance study summary
DesignStand-Alone Performance
PopulationPopulation described in the exact-submission ACR model card
Scopeexact submission
Tested versionExact product version not reported; regulatory study summarized for FDA submission K231690
Samplen=108
IndependenceIndependence not established
K231690
ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K231690. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: Multi-phase volume datasets of reconstructed contrast-enhanced CT scans in DICOM format received from PACS, with physician-identified liver lesions; compatible CT vendors and models are subject to the device labeling's DICOM requirements.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: Multi-phase studies are received from PACS and processing output is transferred back to PACS in DICOM; the device is described as PC-based and self-contained. Exact PACS interfaces, versions, and local compatibility require confirmation.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: The exact FDA package describes iCAS-LV as a PC-based, self-contained, noninvasive image analysis software application. Current hosting, data flow, and commercial configuration require vendor confirmation.
Scope: Exact FDA submission. Packet wording: "It is a PC-based, self-contained, noninvasive image analysis software application.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Confirm processing location, queue ownership, exclusions and exact AI build.
Source context, not route validation: Quantitative liver-lesion volumes and locations in prior and current scans, lesion diameter and volume, total lesion burden, volume and diameter change over time, existing/new/disappeared lesion labels, RECIST measurements, key slices, and DICOM-transferred processing results.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Quantitative liver-lesion volumes and locations in prior and current scans, lesion diameter and volume, total lesion burden, volume and diameter change over time, existing/new/disappeared lesion labels, RECIST measurements, key slices, and DICOM-transferred processing results.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The exact FDA package describes iCAS-LV as a PC-based, self-contained, noninvasive image analysis software application. Current hosting, data flow, and commercial configuration require vendor confirmation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "It is a PC-based, self-contained, noninvasive image analysis software application.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Multi-phase studies are received from PACS and processing output is transferred back to PACS in DICOM; the device is described as PC-based and self-contained. Exact PACS interfaces, versions, and local compatibility require confirmation.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-20Last searched
22Fields reviewed
9Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not verified - checked 2026-09-08 - Exact FDA submission
No public price or quote for the exact K231690 configuration was established in this review.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-09-08 - Exact FDA submission
No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Security: Not verified - checked 2026-09-08 - Exact FDA submission
Exact-release security controls, data retention, hosting boundaries, and scoped assurance documentation require vendor confirmation.
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-09-08 - Exact FDA submission
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
Monitoring: Not verified - checked 2026-09-08 - Exact FDA submission
Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.
Authorized purpose: AI-CVD provides automated quantitative CT-derived anatomical and density measurements for clinician review, including calcium scores, cardiac and vascular measurements, lung and liver density, bone mineral density, and muscle/fat composition; it is opportunistic decision support, not diagnostic interpretation or risk prediction.
Authorized purpose: uOmnispace.CT provides healthcare institutions with tools to view, manipulate, evaluate, and analyze medical CT images, including colon, lung, vessel, brain, cardiac, liver, rib, spine, dual-energy, perfusion, and cardiovascular applications described in the exact FDA submission.
Modality
CT/CTA
Anatomy
Colon, lungs and airway, vessels, brain, heart, liver, ribs, spine, and other CT regions
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.